GHP 2018 Pharmaceutical Manufacturing & Packaging Awards

GHP / Pharmaceutical Manufacturing & Packaging Awards 2018 7 Zoetis. “Zoetis scientists from our laboratory in Beijing and our global R&D network will collaborate with the Suzhou- based R&D team, helping speed the introduction of Zoetis technologies and processes into the development of high-quality vaccines and medicines for China.” The animal vaccines market in China was valued at more than $1.8 billion in 2017. At the start-up R&D laboratory in Suzhou, PHARMAQ scientists will primarily concentrate on acquiring in-depth knowledge of the disease threats within the Chinese aquaculture sector. This know-how will serve as the foundation to develop safe and effective vaccines for the aquaculture industry in China. Vaccines are expected to become an important health management tool for China’s aquaculture industry to help control the diseases that pose the greatest threat to this industry. China is the world`s largest aquaculture nation, producing approximately 50 million metric tonnes of farmed fish in 2016, which represent 63 percent of global production. Increased reliance on vaccines to control disease could help reduce use of antibiotics to treat bacterial disease in farmed fish. Once Zoetis completes construction on the new combined R&D and manufacturing facility, R&D operations will transition to the new facility. “We at Zoetis view China as a global center for high- quality manufacturing as well as innovation,” said Roman Trawicki, Executive Vice President and President of Global Manufacturing and Supply at Zoetis, who officiated at the groundbreaking ceremony. “The completion of this new vaccine manufacturing facility in Suzhou will establish a center of excellence for production of quality vaccines tailored specifically to the needs of the Chinese market. It will broaden our manufacturing capacity and capabilities in China.” The new innovation and manufacturing facility in Suzhou will include 43,000 square meters of vaccine manufacturing operations and laboratory space. Zoetis expects to complete construction and Good Manufacturing Practices certification by the Chinese Ministry of Agriculture by 2021. The site will feature state-of- the-art technologies for the manufacture of viral and bacterial vaccines, and will include pilot scale manufacturing for the development of new vaccine products. Zoetis expects to add approximately 100 new R&D and manufacturing positions at the facility during the next two years. The new facility will become the company’s second vaccine manufacturing site in China. In 2017, Zoetis became the sole owner of its former joint venture vaccine manufacturing site in Jilin where the company has produced vaccines for swine tailored to the needs of the Chinese market since 2011. Innovative products developed there include Rui Lan AnTM, a specialized vaccine launched in 2013 to help control highly pathogenic porcine reproductive and respiratory syndrome (PRRS) identified in China. In 2016, Zoetis also launched Rui Lan Wen™, the first combination vaccine approved in China to help protect pigs against classical swine fever (CSF) and porcine reproductive and respiratory syndrome (PRRS) prevalent there. The new facility will also become the company’s second global manufacturing and supply facility in Suzhou. Zoetis opened a state- of-the-art facility there in 2015 where it produces medicated feed additive products as well as water soluble and pre-mix products used to help raise healthy pigs, cattle, and poultry. Products include Linco-Spectin®, Lincomix®, Tilmicosin® and COT (Check-O-Tox®). This will be particularly important as currently China is the world’s second largest animal health market valued at approximately $4.3 billion USD in 2017 with an expected compound annual growth rate between seven and ten percent. Vaccines continue to be the most significant growth driver. China leads the world in pork production and is home to the world’s largest swine herd with farmers raising 700 million pigs annually. Pet ownership and spending on healthcare is increasing in China. Spending on medicines and vaccines for pets was approximately $300 million in 2017. The animal health industry is devoted to supporting farmers in their work to deliver a safe, wholesome food supply from healthy farm animals and to help pets live longer, healthier lives. Zoetis to Expand Animal Vaccine Research and Manufacturing in Suzhou, China